CD274 and glioblastoma: The administration of anti-TNFRSF14 efficiently improves the sensitivity of GBM cells to anti-PD-L1, and the combined blockade of PD-L1 and TNFRSF14 significantly reduces GBM progression in mouse immune competent model.